Targeted treatments in advanced renal cell carcinoma: focus on axitinib

References

• CohenHTMcGovernFJRenal-cell carcinomaN Engl J Med2005353232477249016339096
   PubMed Web of Science ®Google Scholar
• FerlayJAutierPBoniolMHeanueMColombetMBoylePEstimates of the cancer incidence and mortality in Europe in 2006Ann Oncol200718358159217287242
   PubMed Web of Science ®Google Scholar
• FerlayJParkinDSteliarova-FoucherEEstimates of cancer incidence and mortality in Europe in 2008Eur J Cancer201046476578120116997
   PubMed Web of Science ®Google Scholar
• LinehanWMRiniBIYangJCCancer of the kidneyDe VitaVTHellmannSRosembergSACancer, Principles and Practice of Oncology9th edPhiladelphia, PA, USALippincott Williams & Wilkins, a Wolters Kluwer business201111611182
   Google Scholar
• American Cancer SocietyCancer Facts and FiguresAtlanta, GA, USA2013 Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-028323.pdfAccessed December 19, 2013
   Google Scholar
• MatteiJda SilvaRSehrtDMolinaWKimFTargeted therapy in metastatic renal carcinomaCancer Lett2013piiS03043835(13)00707-624239667
   PubMed Web of Science ®Google Scholar
• PortaCZimatoreMImarisioIGemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II studyCancer2004100102132213815139055
   PubMed Web of Science ®Google Scholar
• TamaskarIPiliRUpdate on novel agents in renal cell carcinomaExpert Rev Anticancer Ther20099121817182719954293
   PubMed Web of Science ®Google Scholar
• HowladerNNooneAMKrapchoMSEER Cancer Statistics Review, 1975–2010Bethesda, MD, USANational Cancer Institute2013 Available from: http://seer.cancer.gov/csr/1975_2010/Accessed December 19, 2013
   Google Scholar
• NegrierSEscudierBLassetCRecombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’ImmunotherapieN Engl J Med199833818127212789562581
   PubMed Web of Science ®Google Scholar
• AtkinsMBReganMMcDermottDUpdate on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinomaClin Cancer Res20041018 Pt 26342S6346S15448028
   PubMed Web of Science ®Google Scholar
• NegrierSPerolDRavaudAMedroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trialCancer2007110112468247717932908
   PubMed Web of Science ®Google Scholar
• MotzerREscudierBOudardSEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialLancet2008372963744945618653228
   PubMed Web of Science ®Google Scholar
• MolinaAMotzerRClinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrowOncologist201116Suppl 2455021346039
   PubMed Web of Science ®Google Scholar
• MolinaAFeldmanDVossMPhase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinomaCancer201211871868187621898375
   PubMed Web of Science ®Google Scholar
• HutsonTETargeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidenceOncologist201116Suppl 2142221346036
   PubMed Web of Science ®Google Scholar
• PatardJ-JPignotGEscudierBICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic diseaseEur Urol201160468469021704448
   PubMed Web of Science ®Google Scholar
• LjungbergBCowanNHanburyDEAU guidelines on renal cell carcinoma: the 2010 updateEur Urol201058339840620633979
   PubMed Web of Science ®Google Scholar
• MotzerRAgarwalNBeardCNCCN clinical practice guidelines in oncology: kidney cancerJ Natl Compr Canc Netw20097661863019555584
   PubMed Web of Science ®Google Scholar
• EscudierBPluzanskaAKoralewskiPBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet200737096052103211118156031
   PubMed Web of Science ®Google Scholar
• EscudierBEisenTStadlerWMSorafenib in advanced clear-cell renal-cell carcinomaN Engl J Med2007356212513417215530
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med2007356211512417215529
   PubMed Web of Science ®Google Scholar
• RiniBIHalabiSRosenbergJEPhase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206J Clin Oncol201028132137214320368558
   PubMed Web of Science ®Google Scholar
• SternbergCNDavisIDMardiakJPazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trialJ Clin Oncol20102861061106820100962
   PubMed Web of Science ®Google Scholar
• HanahanDWeinbergRAHallmarks of cancer: the next generationCell2011144564667421376230
   PubMed Web of Science ®Google Scholar
• HudesGCarducciMTomczakPTemsirolimus, interferon alfa, or both for advanced renal-cell carcinomaN Engl J Med2007356222271228117538086
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBOudardSPhase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factorsCancer2010116184256426520549832
   PubMed Web of Science ®Google Scholar
• RiniBIEscudierBTomczakPComparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialLancet201137898071931193922056247
   PubMed Web of Science ®Google Scholar
• DabneyRDevineRSeinNGeorgeBNew agents in renal cell carcinomaTarget Oncol11162013 Epub ahead of print
   PubMed Web of Science ®Google Scholar
• PatsonBCohenRBOlszanskiAJPharmacokinetic evaluation of axitinibExpert Opin Drug Metab Toxicol20128225927022248343
   PubMed Web of Science ®Google Scholar
• BukowskiRThird generation tyrosine kinase inhibitors and their development in advanced renal cell carcinomaFront Oncol201221322655261
   PubMedGoogle Scholar
• Hu-LoweDZouHGrazziniMNonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3Clin Cancer Res200814227272728319010843
   PubMed Web of Science ®Google Scholar
• RugoHHerbstRLiuGPhase I trial of the oral antiangio-genesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical resultsJ Clin Oncol200523245474548316027439
   PubMed Web of Science ®Google Scholar
• PithavalaYTortoriciMTohMEffect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteersCancer Chemother Pharmacol201065356357019603168
   PubMed Web of Science ®Google Scholar
• PollerBIusufDSparidansRWagenaarEBeijnenJSchinkelADifferential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokineticsDrug Metab Dispos201139572973521282407
   PubMed Web of Science ®Google Scholar
• MignognaCStaibanoSAltieriVPrognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysisBMC Cancer2006629317177989
   PubMed Web of Science ®Google Scholar
• PithavalaYTongWMountJEffect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteersInvest New Drugs201230127328120740300
   PubMed Web of Science ®Google Scholar
• HoskinsJMGoldbergRMQuPIbrahimJGMcLeodHLUGT1A1*28 genotype and irinotecan-induced neutropenia: dose mattersJ Natl Cancer Inst200799171290129517728214
   PubMedGoogle Scholar
• YapKYChuiWKChanADrug interactions between chemotherapeutic regimens and antiepilepticsClin Ther20083081385140718803983
   PubMed Web of Science ®Google Scholar
• KiranPTypical drug interactions in oncologyUS Pharm201136179
   Google Scholar
• PithavalaYKChenYTohMEvaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteersCancer Chemother Pharmacol201270110311222644797
   PubMed Web of Science ®Google Scholar
• RixeOBukowskiRMMichaelsonMDAxitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II studyLancet Oncol200781197598417959415
   PubMed Web of Science ®Google Scholar
• RiniBIWildingGHudesGPhase II study of axitinib in sorafenib-refractory metastatic renal cell carcinomaJ Clin Oncol200927274462446819652060
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBTomczakPAxitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trialLancet Oncol201314655256223598172
   PubMed Web of Science ®Google Scholar
• AmirESerugaBKwongRTannockIFOcanaAPoor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?Eur J Cancer201248338538822115991
   PubMed Web of Science ®Google Scholar
• RiniBIMelicharBUedaTAxitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trialLancet Oncol201314121233124224140184
   PubMed Web of Science ®Google Scholar
• HutsonTELesovoyVAl-ShukriSAxitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trialLancet Oncol201314131287129424206640
   PubMed Web of Science ®Google Scholar
• HutsonTEEscudierBEstebanERandomized Phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinomaJ Clin Oncol1222013 Epub ahead of print
   Web of Science ®Google Scholar
• MotzerRJNosovDEisenTTivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trialJ Clin Oncol201331303791379924019545
   PubMed Web of Science ®Google Scholar
• EscudierBGoreMAxitinib for the management of metastatic renal cell carcinomaDrugs R D201111211312621679004
   PubMedGoogle Scholar
• CohenRBOudardSAntiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicitiesInvest New Drugs20123052066207922327313
   PubMed Web of Science ®Google Scholar
• LarkinJFishmanMWoodLAxitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomesAm J Clin Oncol1242013 Epub ahead of print
   Web of Science ®Google Scholar
• CellaDEscudierBRiniBPatient-reported outcomes for axitinib versus sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trialBr J Cancer201310881571157823579211
   PubMed Web of Science ®Google Scholar
• PaytonSKidney cancer: AXIS trial data confirm axitinib as second-line option for mRCCNat Rev Urol201310630823649292
   PubMedGoogle Scholar
• EscudierBEisenTPortaCRenal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201223Suppl 7vii65vii7122997456
   PubMed Web of Science ®Google Scholar